Drug intelligence / Profile preview

WT001

Development stage: Preclinical
Lead developer: Windtree Therapeutics
Modality: Peptides

Overview

**WT001** is an uncharacterized respiratory drug-development code attributed in the provided historical Lee's Pharmaceutical pipeline extraction to Lee's Pharmaceutical and ZKGZ Biotech. No INN, chemical structure, molecular target, modality, formulation, route of administration, or specific respiratory indication has been publicly substantiated. It should be retained as a distinct code-level asset and should not be conflated with other respiratory products associated with Lee's Pharmaceutical or its partners.

Brand names: AEROSURF
Other names: lucinactant for inhalationaerosolized lucinactant

Beyond the preview

Go deeper on WT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT001.

Explore the full profile